Coherus BioSciences Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $102,891 | | $63,547 | ||
| Investments in marketable securities | | | 14,857 | | | 128,134 |
| Trade receivables, net | | 260,522 | | 109,964 | ||
| Inventory | | 62,605 | | 38,791 | ||
| Prepaid manufacturing | | 23,657 | | 17,880 | ||
| Other prepaids and current assets | | 11,099 | | 22,918 | ||
| Total current assets | | 475,631 | | 381,234 | ||
| Property and equipment, net | | 5,119 | | 8,754 | ||
| Inventory, non-current | | 67,495 | | 76,260 | ||
| Intangible assets, net | | 71,673 | | 5,931 | ||
| Other assets, non-current | | 9,686 | | 8,668 | ||
| Total assets | | $629,604 | | $480,847 | ||
| | | | | | | |
| Liabilities and Stockholders’ Deficit | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $35,219 | | $11,526 | ||
| Accrued rebates, fees and reserves | | 169,645 | | 54,461 | ||
| Accrued compensation | | 21,521 | | 22,610 | ||
| Accrued and other current liabilities | | 105,386 | | 50,097 | ||
| Total current liabilities | | 331,771 | | 138,694 | ||
| Term loans | | | 246,481 | | | 245,483 |
| Convertible notes | | | 226,888 | | | 225,575 |
| Lease liabilities, non-current | | 5,328 | | 5,046 | ||
| Other liabilities, non-current | | 12,561 | | 3,467 | ||
| Total liabilities | | 823,029 | | 618,265 | ||
| Commitments and contingencies (Note 9) | | | ||||
| Stockholders’ deficit: | | | ||||
| Preferred stock ($0.0001 par value; shares authorized: 5,000,000; shares issued and outstanding: 0 at December 31, 2023 and 2022) | | | — | | | — |
| Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 112,215,260 and 78,851,516 at December 31, 2023 and 2022, respectively) | | 11 | | 8 | ||
| Additional paid-in capital | | 1,386,312 | | 1,204,431 | ||
| Accumulated other comprehensive loss | | (248) | | (249) | ||
| Accumulated deficit | | (1,579,500) | | (1,341,608) | ||
| Total stockholders' deficit | | (193,425) | | (137,418) | ||
| Total liabilities and stockholders’ deficit | | $629,604 | | $480,847 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.